Inactive Instrument

DEINOVE Stock price

Equities

ALDEI

FR0010879056

Renewable Fuels

Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 21-02-16
Chief Executive Officer 74 17-03-01
Director of Finance/CFO - -
Members of the board TitleAgeSince
74 -
Director/Board Member 62 17-05-15
Director/Board Member - 10-01-26
More insiders
DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the "microbial dark matter". By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed. Nowadays, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the World primary emergencies.
More about the company
  1. Stock
  2. Equities
  3. Stock DEINOVE - Euronext Paris